Use of Benzodiazepines and Z-Drugs in Inflammatory Bowel Disease
Article 2022 en
Authors
ÇB
Çharles N. Bernstein
JF
John D. Fisk
RW
Randy Walld
Abstract
1 min read
The use of BZD is more common in people with IBD than in population controls. Strategies to reduce the use of BZDs in persons with IBD and to offer alternative management strategies for M/ADs, sleep disorders, and other symptomatic concerns are needed.
Ruth Ann Marrie, John D. Fisk, Randy Walld, James M. Bolton, Jitender Sareen, Scott Burton Patten, Alexander Singer, Lisa M. Lix, Carol Hitchon, Renée El‐Gabalawy, Alan Katz, James Marriott, Çharles N. Bernstein
Çharles N. Bernstein, Carol Hitchon, Randy Walld, James M. Bolton, Jitender Sareen, John R. Walker, Lesley A. Graff, Scott Burton Patten, Alexander Singer, Lisa M. Lix, Renée El‐Gabalawy, Alan Katz, John D. Fisk, Ruth Ann Marrie
Çharles N. Bernstein, John D. Fisk, Randy Walld, Jitender Sareen, Scott Burton Patten, Alexander Singer, Lisa M. Lix, Carol Hitchon, Renée El‐Gabalawy, Alan Katz, Lesley A. Graff, Jitender Sareen, Scott Burton Patten, Alexander Singer, Lisa M. Lix, Carol Hitchon, Renée El‐Gabalawy, John D. Fisk, Lesley A. Graff, Lindsay Berrigan, Ryan Zarychanski, Christine Peschken,
Discussion(0)
No comments yet. Be the first to comment.